학술논문

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
Document Type
article
Source
Hepatology. 71(1)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Hepatitis - C
Hepatitis
Liver Disease
Clinical Trials and Supportive Activities
Infectious Diseases
Chronic Liver Disease and Cirrhosis
Clinical Research
Emerging Infectious Diseases
Pediatric
Digestive Diseases
Management of diseases and conditions
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
7.1 Individual care needs
Infection
Good Health and Well Being
Antiviral Agents
Child
Child
Preschool
Drug Combinations
Female
Genotype
Hepacivirus
Hepatitis C
Chronic
Humans
Male
Ribavirin
Sofosbuvir
Sustained Virologic Response
Treatment Outcome
Medical Biochemistry and Metabolomics
Immunology
Gastroenterology & Hepatology
Clinical sciences
Language
Abstract
Currently, the only approved hepatitis C virus (HCV) treatment for children aged